Fox Foundation for Parkinson’s Research (MJFF). Operating and Financial Review and Prospects" in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. The development of alpha-synuclein pathology appears to correlate with the loss of dopaminergic neurons and subsequent decline in motor performance, making it a highly relevant molecular target for diagnostic approaches. These risks and uncertainties include those described under the captions "Item 3. Andrea Pfeifer, CEO of AC Immune, said: "We are honored to receive continued funding from The Michael J. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Promising small molecules have been identified with good selectivity for alpha-synuclein and suitable properties for the development as PET ligands. This technology has multiple advantages including direct detection of alpha-synuclein pathology in patients and the capacity to monitor the efficacy of therapeutics reducing alpha-synuclein aggregates in clinical trials., a wholly owned subsidiary of Roche. Forward looking statements This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. AC Immune expects to move the program into clinical development in 2018. We continue to leverage our proprietary technology platforms, developing both diagnostic and therapeutic agents for multiple neurodegenerative diseases. Key Information-Risk Factors" and "Item 5. Through the radio-tracer on the tracer molecule, the imaging device detects the bound alpha-synuclein imaging agent and creates pictures reflecting the amount and distribution of pathological alpha-synuclein in the brain. In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. We are pleased with the progress of the AC Immune program toward this critical goal," commented Jamie Eberling, PhD, director of research programs at MJFF. AC Immune’s proprietary MorphomerTM chemistry technology platform is designed to interact with misfolded and aggregated proteins. No alpha-synuclein-PET tracer has received regulatory approval for commercial distribution, which represents an important medical need, not only in Parkinson’s disease but also in other synucleinopathies such as dementia with Lewy bodies and multiple system atrophy. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. About alpha-synuclein-PET tracers A brain Positron Emission Tomography (PET) scan is an imaging test of the brain involving an Electric Motors Factory https://www.lbdcmotor.com/ imaging device and an imaging agent called a PET tracer.lbdcmotor. We aim to move this PET tracer program into the clinic in 2018. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. Parkinson’s disease affects approximately 1% of individuals older than 60 years and causes progressive disability (motor and non-motor symptoms). The support of MJFF further validates AC Immune’s leading expertise in the pathology of misfolded proteins.